Published in:
Open Access
17-03-2022 | Positron Emission Tomography | Short Communication
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
Authors:
Matthew J. Roberts, Andrew Morton, Nathan Papa, Anthony Franklin, Sheliyan Raveenthiran, William J. Yaxley, Geoffrey Coughlin, Troy Gianduzzo, Boon Kua, Louise McEwan, David Wong, Brett Delahunt, Lars Egevad, Hemamali Samaratunga, Nicholas Brown, Robert Parkinson, Louise Emmett, John W. Yaxley
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 9/2022
Login to get access
Abstract
Purpose
The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy.
Methods
We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and 68 Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis.
Results
After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters.
Conclusion
These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS.